Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan


  • Efrain Antonio GonzalezEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_9271

Generic Name


Brand Name

Invega, Invega Sustenna, Invega Trinza


Antipsychotics, second generation, mood stabilizer

Proposed Mechanism(s) of Action

Combination of central dopamine D2 and serotonin 5-HT2A receptor antagonism


For the treatment of schizophrenia and manic or mixed bipolar 1 episodes

Off-Label Use

Agitation associated with a myriad of psychiatric conditions and dementia. Borderline personality disorder. Disruptive behavioral disorders associated with childhood.

Side Effects


Increased risk of mortality in elderly patients with dementia-related psychosis, mania. Extrapyramidal symptoms, prolongation of Q-T interval, agranulocytosis.


Headache, dizziness, somnolence, dry mouth, nausea, tachycardia, diarrhea, orthostatic hypotension, weight gain.

References and Readings

  1. Physicians’ desk reference (71st ed.) (2017). Montvale: Thomson PDR.Google Scholar
  2. Stahl, S. M. (2007). Essential psychopharmacology: The prescriber’s guide (2nd ed.). New York: Cambridge University Press.Google Scholar

Additional Information

  1. Frånberg, O., Marcus, M. M., Ivanov, V., Schilström, B., Shahid, M., & Svensson, T. H. (2009). Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology, 204(2), 251–264.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Free Drug Online. www.medscape.com
  3. Free Drug Online and PDA Software. www.epocrates.com
  4. Marston, H. M., Young, J. W., Martin, F. D., Serpa, K. A., Moore, C. L., Wong, E. H., Gold, L., Meltzer, L. T., Azar, M. R., Geyer, M. A., & Shahid, M. (2009). Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology, 206(4), 699–714.PubMedCentralCrossRefPubMedGoogle Scholar
  5. Potkin, S. G., Cohen, M., & Panagides, J. (2007). Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial. The Journal of Clinical Psychiatry, 68(10), 1492–1500.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.College of PsychologyNova Southeastern UniversityFort LauderdaleUSA
  2. 2.Utah State UniversityLoganUSA